Oncocyte said after the close of the market on Wednesday that its fourth quarter net loss rose 77 percent year over year as it pushed toward a transition to commercial test operations.

Biocept said after the close of the market on Wednesday that its fourth quarter revenues more than doubled year over year, driven by 46 percent growth in commercial test volume and 34 percent growth in average insurance reimbursement per patient.

HTG Molecular Diagnostics reported after the close of the market on Wednesday an 11 percent year-over-year drop in its full-year revenues, driven by a significant decrease in collaboration revenue.

Quidel said after the close of the market on Wednesday that it has received expanded Emergency Use Authorization from the US Food and Drug Administration for the Lyra SARS-CoV-2 assay.

The Association of the British Pharmaceutical Industry (ABPI) has issued a statement.

Swift Biosciences has partnered with LGC Biosearch Technologies to incorporate Swift's targeted sequencing technology into LGC's kits and service offerings for the worldwide ag-bio market.

Natera reported after the close of the market on Wednesday that its fourth quarter 2019 revenues grew 24 percent year over year.

Swift Biosciences has partnered with LGC Biosearch Technologies to incorporate Swift's targeted sequencing technology into LGC's kits and service offerings for the worldwide ag-bio market.

Illumina has asked a US Court for a preliminary injunction to prevent BGI from distributing sequencers in the US to a handful of labs on a no-cost trial basis.

Fluidigm said on Wednesday that it has completed the acquisition of InstruNor, a privately held, Oslo-based provider of integrated sample preparation systems for flow and mass cytometry.

The US International Trade Commission has upheld a judge's previous determination that certain microfluidic products imported by Bio-Rad Laboratories indirectly infringe patents held by 10x Genomics.

BioMérieux reported today that its fourth quarter revenues rose 11 percent year over year driven by sales of molecular biology reagents and microbiology instruments, as well as a strong dynamic in Asia Pacific.

Adaptive Biotechnologies reported after the close of the market on Wednesday that its fourth quarter revenues increased 41 percent year over year.

Grail is making some headway in its mission to develop a liquid biopsy solution to detect cancer early. The Menlo Park, CA-based company said it has initiated PATHFINDER, a multi-center study.

Quest Diagnostics said it has acquired Blueprint Genetics in an all-cash equity transaction.